

Richard Ceska

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3612579/richard-ceska-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

96 papers	5,916 citations	27 h-index	76 g-index
141 ext. papers	6,722 ext. citations	5.8 avg, IF	5.01 L-index

#	Paper	IF	Citations
96	Familial Hypercholesterolemia: Real-World Data of 1236 Patients Attending a Czech Lipid Clinic. A Retrospective Analysis of Experience in More than 50 years. Part I: Genetics and Biochemical Parameters.. <i>Frontiers in Genetics</i> , 2022 , 13, 849008	4.5	1
95	Familial Hypercholesterolemia: Real-World Data of 1236 Patients Attending a Czech Lipid Clinic. A Retrospective Analysis of Experience in More than 50 years. Part II. Clinical Characteristics.. <i>Frontiers in Genetics</i> , 2022 , 13, 849267	4.5	1
94	PCSK9 Inhibitors in Real-world Practice: Analysis of Data from 314 Patients and 2 Years of Experience in a Center of Preventive Cardiology.. <i>Current Atherosclerosis Reports</i> , 2022 , 1	6	1
93	An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial. <i>JAMA Cardiology</i> , 2020 , 5, 709-713	16.2	25
92	Statin Intolerance in Clinical Practice. <i>Current Atherosclerosis Reports</i> , 2020 , 22, 27	6	3
91	Statin therapy in athletes and patients performing regular intense exercise - Position paper from the International Lipid Expert Panel (ILEP). <i>Pharmacological Research</i> , 2020 , 155, 104719	10.2	7
90	The Gene Score for Predicting Hypertriglyceridemia: New Insights from a Czech Case-Control Study. <i>Molecular Diagnosis and Therapy</i> , 2019 , 23, 555-562	4.5	6
89	The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH Project. <i>Current Atherosclerosis Reports</i> , 2019 , 21, 36	6	9
88	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation. <i>Cardiovascular Diabetology</i> , 2019 , 18, 71	8.7	64
87	Strong Association between APOA5 Gene Polymorphisms and Hypertriglyceridaemic Episodes. <i>Folia Biologica</i> , 2019 , 65, 188-194	0.7	2
86	Comments on the most important and recent studies involving PCSK9i. <i>Vnitřní Lekarství</i> , 2018 , 64, 1137-1141	11.4	141
85	Body Adiposity Changes After Lifestyle Interventions in Children/Adolescents and the NYD-SP18 and TMEM18 Variants. <i>Medical Science Monitor</i> , 2018 , 24, 7493-7498	3.2	4
84	A comprehensive guidelines-based approach reduces cardiovascular risk in everyday practice: the VARO study. <i>Archives of Medical Science</i> , 2017 , 13, 705-710	2.9	8
83	ScreenPro FH: from the Czech MedPed to international collaboration. ScreenPro FH is a participating project of the EAS-FHCS. <i>Physiological Research</i> , 2017 , 66, S85-S90	2.1	6
82	Familial hypercholesterolemia in the Czech Republic: more than 17 years of systematic screening within the MedPed project. <i>Physiological Research</i> , 2017 , 66, S1-S9	2.1	12
81	Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial. <i>Clinical Cardiology</i> , 2016 , 39, 137-44	3.3	25
80	Gene variants at FTO, 9p21, and 2q36.3 are age-independently associated with myocardial infarction in Czech men. <i>Clinica Chimica Acta</i> , 2016 , 454, 119-23	6.2	10

79	Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 315, 1580-90	27.4	307
78	Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. <i>New England Journal of Medicine</i> , 2015 , 372, 1489-99	59.2	1347
77	Association between polymorphism within the RYR2 receptor and development of statin-associated myalgia/myopathy in the Czech population. <i>European Journal of Internal Medicine</i> , 2015 , 26, 367-8	3.9	8
76	Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. <i>Expert Opinion on Drug Safety</i> , 2015 , 14, 935-55	4.1	94
75	Statin Intolerance: the Clinician's Perspective. <i>Current Atherosclerosis Reports</i> , 2015 , 17, 69	6	38
74	ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. <i>European Heart Journal</i> , 2015 , 36, 2996-3003	9.5	311
73	Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. <i>Archives of Medical Science</i> , 2015 , 11, 1-23	2.9	252
72	SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population. <i>Medical Science Monitor</i> , 2015 , 21, 1454-9	3.2	22
71	The Impact of Physical Activity and Dietary Measures on the Biochemical and Anthropometric Parameters in Obese Children. Is There Any Genetic Predisposition?. <i>Central European Journal of Public Health</i> , 2015 , 23 Suppl, S62-6	1.2	6
70	Treatment of hypertriglyceridemia: a review of current options. <i>Physiological Research</i> , 2015 , 64, S331-40.	40.1	18
69	Implementation of cardiovascular disease prevention guidelines into clinical practice: an unmet challenge?. <i>Current Pharmaceutical Design</i> , 2015 , 21, 1180-4	3.3	1
68	A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. <i>New England Journal of Medicine</i> , 2014 , 370, 1809-19	59.2	506
67	Statins, glycemia, and diabetes mellitus: another point of view. <i>Current Atherosclerosis Reports</i> , 2014 , 16, 458	6	4
66	Combined therapy of mixed dyslipidemia in patients with high cardiovascular risk and changes in the lipid target values and atherogenic index of plasma. <i>Cor Et Vasa</i> , 2014 , 56, e133-e139	0.3	2
65	Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Diabetes and Endocrinology</i> , 2014 , 2, 455-63	18.1	68
64	The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice. <i>Atherosclerosis Supplements</i> , 2014 , 15, 1-15	1.7	62
63	Ivabradine in stable coronary artery disease. <i>New England Journal of Medicine</i> , 2014 , 371, 2435	59.2	11
62	Ivabradine, coronary heart disease, and heart failure: time for reappraisal. <i>Current Atherosclerosis Reports</i> , 2014 , 16, 463	6	2

61	Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 1870-82	27.4	347
60	Rosiglitazone influences the expression of leukocyte adhesion molecules and CD14 receptor in type 2 diabetes mellitus patients. <i>Physiological Research</i> , 2014 , 63, S293-8	2.1	5
59	Statin-associated myopathy: from genetic predisposition to clinical management. <i>Physiological Research</i> , 2014 , 63, S327-34	2.1	37
58	FTO and MC4R gene variants determine BMI changes in children after intensive lifestyle intervention. <i>Clinical Biochemistry</i> , 2013 , 46, 313-6	3.5	27
57	Statin therapy is a major determinant of PCSK9 plasma concentration: data from four clinical trials with AMG 145. <i>European Heart Journal</i> , 2013 , 34, P681-P681	9.5	
56	Variant within CELSR2/PSRC1/SORT1, but not within CILP2/PBX4, PCSK9 and APOB genes, has a potential to influence statin treatment efficacy. <i>Journal of Applied Biomedicine</i> , 2012 , 10, 19-28	0.6	4
55	APOA5 haplotypes determine triglyceride decrease after lifestyle induced weight loss in children. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2012 , 22, e22-3	4.5	3
54	Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. <i>Diabetes Care</i> , 2012 , 35, 1232-8	14.6	339
53	Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. <i>PLoS ONE</i> , 2012 , 7, e49006	3.7	165
52	Impact of variants within seven candidate genes on statin treatment efficacy. <i>Physiological Research</i> , 2012 , 61, 609-17	2.1	16
51	Possible gene-gender interaction between the SLCO1B1 polymorphism and statin treatment efficacy. <i>Neuroendocrinology Letters</i> , 2012 , 33 Suppl 2, 22-5	0.3	6
50	Plasma HDL-cholesterol and triglyceride levels in familial hypercholesterolemia: data from the MedPed CZ database and the Czech population. <i>Clinica Chimica Acta</i> , 2011 , 412, 920-4	6.2	4
49	Drug-drug interactions with statins: will pitavastatin overcome the statinsS AchillesSheel?. <i>Current Medical Research and Opinion</i> , 2011 , 27, 1551-62	2.5	41
48	Efficacy and safety of extended-release niacin/laropirant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia. <i>International Journal of Clinical Practice</i> , 2010 , 64, 727-38	2.9	23
47	Ultrasound protocols to measure carotid intima-media thickness in trials; comparison of reproducibility, rate of progression, and effect of intervention in subjects with familial hypercholesterolemia and subjects with mixed dyslipidemia. <i>Annals of Medicine</i> , 2010 , 42, 447-64	1.5	40
46	Interaction of common sequence variants and selected risk factors in determination of HDL cholesterol levels. <i>Clinical Biochemistry</i> , 2010 , 43, 754-8	3.5	3
45	Impact of apolipoprotein A5 variants on statin treatment efficacy. <i>Pharmacogenomics</i> , 2009 , 10, 945-50	2.6	30
44	The apo(a) gene (TTTA) _n promoter polymorphism and its association with variability in exons of the kringle IV types 8 to 10. <i>Clinica Chimica Acta</i> , 2009 , 405, 39-42	6.2	4

43	The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia. <i>American Journal of Cardiology</i> , 2008 , 102, 1K-34K	3	280
42	Oral but not transdermal estrogen replacement therapy changes the composition of plasma lipoproteins. <i>Metabolism: Clinical and Experimental</i> , 2008 , 57, 1088-92	12.7	39
41	Prevention of diabetes with rosiglitazone: Evidence of benefit or unexpected harm?. <i>Medical Hypotheses</i> , 2008 , 70, 199-200	3.8	1
40	IMPACT OF APOLIPOPROTEIN A5 GENE VARIANTS ON STATIN TREATMENT EFFICACY. <i>Atherosclerosis Supplements</i> , 2008 , 9, 40	1.7	2
39	APOA5 Ala315>Val, identified in patients with severe hypertriglyceridemia, is a common mutation with no major effects on plasma lipid levels. <i>Clinical Chemistry and Laboratory Medicine</i> , 2008 , 46, 773-7	5.9	10
38	The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. <i>Diabetes and Vascular Disease Research</i> , 2008 , 5, 319-35	3.3	192
37	MLXIPL variant in individuals with low and high triglyceridemia in white population in Central Europe. <i>Human Genetics</i> , 2008 , 124, 553-5	6.3	25
36	Hyperlipidemia is associated with altered levels of insulin-like growth factor-I. <i>Physiological Research</i> , 2008 , 57, 919-925	2.1	10
35	Type III hyperlipoproteinaemia and primary amenorrhoea associated with severe hypothyroidism. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2007 , 89, 1023-1024	3.1	2
34	Variability in apo(a) gene regulatory sequences, compound genotypes, and association with Lp(a) plasma levels. <i>Clinical Biochemistry</i> , 2007 , 40, 802-5	3.5	3
33	Clinical implications of the metabolic syndrome. <i>Diabetes and Vascular Disease Research</i> , 2007 , 4 Suppl 3, S2-4	3.3	11
32	Folic acid does not improve surrogate markers of early atherosclerosis in atorvastatin-treated patients. <i>Nutrition Research</i> , 2007 , 27, 181-185	4	1
31	Detection of variability in apo(a) gene transcription regulatory sequences using the DGGE method. <i>Clinica Chimica Acta</i> , 2007 , 376, 77-81	6.2	11
30	Is it safe to combine PPAR agonists? A lesson from muraglitazar. <i>Medical Hypotheses</i> , 2006 , 67, 669	3.8	
29	Effect of rosiglitazone on homocysteine and creatinine levels in patients with type 2 diabetes. <i>Atherosclerosis</i> , 2005 , 183, 367-8	3.1	7
28	Cholesterol-lowering therapy evokes time-limited changes in serotonergic transmission. <i>Psychiatry Research</i> , 2005 , 133, 197-203	9.9	67
27	Hypertriglyceridemia: interaction between APOE and APOAV variants. <i>Clinical Chemistry</i> , 2005 , 51, 1311-35	3.5	13
26	New strategies in the treatment of dyslipidemia: do we know how?. <i>Seminars in Vascular Medicine</i> , 2004 , 4, 305-10		

25	Effect of simvastatin and fenofibrate on endothelium in Type 2 diabetes. <i>European Journal of Pharmacology</i> , 2004 , 493, 183-9	5.3	26
24	Hypolipidemic drugs, blood pressure, heart rate, heart rate variability and sympathetic activity. <i>International Congress Series</i> , 2004 , 1262, 458-461		2
23	PAPP-A, a novel marker of unstable plaque, is not influenced by hypolipidemic treatment in contrast to CRP. <i>Atherosclerosis</i> , 2003 , 166, 195-6	3.1	6
22	Atorvastatin reduces expression of leukocyte adhesion molecules in patients with hypercholesterolemia. <i>Atherosclerosis</i> , 2003 , 166, 197-8	3.1	8
21	T-1131-->C polymorphism within the apolipoprotein AV gene in hypertriglyceridemic individuals. <i>Atherosclerosis</i> , 2003 , 167, 369-70	3.1	40
20	Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine. <i>American Heart Journal</i> , 2003 , 146, 110	4.9	17
19	Increased levels of pregnancy-associated plasma protein-A in patients with hypercholesterolemia: the effect of atorvastatin treatment. <i>American Heart Journal</i> , 2003 , 146, E21	4.9	20
18	Effect of atorvastatin and fenofibrate on autonomic tone in subjects with combined hyperlipidemia. <i>American Journal of Cardiology</i> , 2003 , 92, 337-41	3	24
17	Increase of inflammatory state in overweight adults with combined hyperlipidemia. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2003 , 13, 227-31	4.5	7
16	Ser19-->Trp polymorphism within the apolipoprotein AV gene in hypertriglyceridaemic people. <i>Journal of Medical Genetics</i> , 2003 , 40, e105	5.8	20
15	Apolipoprotein AV gene polymorphisms (T-1131/C and Ser19/Trp) influence plasma triglyceride levels and risk of myocardial infarction. <i>Experimental and Clinical Cardiology</i> , 2003 , 8, 151-4		6
14	Microvascular reactivity in patients with hypercholesterolemia: effect of lipid lowering treatment. <i>Physiological Research</i> , 2003 , 52, 439-45	2.1	17
13	Nitroglycerin induced syncope occurs in subjects with delayed phase shift of baroreflex action. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2002 , 25, 828-32	1.6	6
12	Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. <i>American Heart Journal</i> , 2002 , 144, G1-G8	4.9	10
11	Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. <i>American Heart Journal</i> , 2002 , 144, E6	4.9	46
10	Folate supplementation prevents plasma homocysteine increase after fenofibrate therapy. <i>Nutrition</i> , 2001 , 17, 721-3	4.8	49
9	Flow-dependent vasomotor dysfunction of the popliteal artery related to common carotid artery intima-media thickness. <i>Angiology</i> , 2001 , 52, 689-95	2.1	1
8	Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT). <i>Cardiovascular Research</i> , 2001 , 52, 290-8	9.9	112

7	Serum leptin levels in patients with hyperlipidemias. <i>Nutrition</i> , 2000 , 16, 429-33	4.8	25
6	Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes. <i>Journal of Clinical Investigation</i> , 2000 , 106, 1263-70	15.9	266
5	Familial defective apolipoprotein B-100 homozygote with premature coronary atherosclerosis. A case report. <i>Journal of Internal Medicine</i> , 1999 , 246, 235-6	10.8	4
4	Apoe genotype is not associated with variations in bone mineral density. <i>Atherosclerosis</i> , 1999 , 144, 103-104	3.04	8
3	Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group. <i>American Journal of Cardiology</i> , 1998 , 81, 912-7	3	158
2	Decreasing common carotid artery intimal thickness during hypolipidemic therapy. <i>Angiology</i> , 1997 , 48, 761-7	2.1	3
1	Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP). <i>Journal of Cachexia, Sarcopenia and Muscle</i> ,	10.3	3